[Federal Register Volume 85, Number 89 (Thursday, May 7, 2020)]
[Notices]
[Pages 27245-27246]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-09705]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-638]


Importer of Controlled Substances Application: Novitium Pharma 
LLC

ACTION: Notice of application.

-----------------------------------------------------------------------

DATES: Registered bulk manufacturer of the affected basic class(es), 
and applicants therefore, may file written comments on or objections to 
the issuance of the proposed registration on or before June 8, 2020. 
Such persons may also file a written request for a hearing on the 
application on or before June 8, 2020.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/DPW, 
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a 
hearing must be sent to: Drug Enforcement Administration, Attn: 
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All 
requests for a hearing should also be sent to: (1) Drug Enforcement 
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, 
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,

[[Page 27246]]

Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, 
Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this 
is notice that on March 2, 2020, Novitium Pharma LLC, 70 Lake Drive, 
East Windsor, New Jersey 08520, applied to be registered as an importer 
of the following basic class(es) of controlled substances:

------------------------------------------------------------------------
         Controlled substance           Drug code         Schedule
------------------------------------------------------------------------
Lisdexamfetamine.....................       1205   II
------------------------------------------------------------------------

    The company plans to import the listed controlled substance as a 
raw material for drug product development and research.
    The company may import Active Pharmaceutical Ingredients (API) for 
research purposes only but not for the manufacturing of Food and Drug 
Administration-approved products. Approval of permit applications will 
occur only when the registrant's activity is consistent with what is 
authorized under 21 U.S.C. 952(a)(2).

William T. McDermott,
Assistant Administrator.
[FR Doc. 2020-09705 Filed 5-6-20; 8:45 am]
 BILLING CODE 4410-09-P